Browsing: Preclinical

The Lancet Diabetes & Endocrinology Commission redefined obesity by considering both anthropometric and direct measures of adiposity, in addition to body mass index (BMI), and distinguishing preclinical from clinical obesity based on physical function and related conditions. However, the frequency and determinants of progression from preclinical to clinical obesity have never been studied

COMBINED tau biomarkers track early cognitive decline and forecast structural neurodegeneration in preclinical Alzheimer’s disease. Clinicians evaluating asymptomatic individuals with confirmed amyloid-beta deposition frequently face significant prognostic challenges due to variable disease trajectories. While plasma biomarkers offer high diagnostic sensitivity, they lack spatial precision regarding fibrillar protein localization in specific neural tissues. To address these…